clinical trial · NCT04743141
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Acute Treatment of MigraineRimegepant (PF-07899801)
brief summary
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
started
Apr 28, 2021
primary completion
Jul 31, 2030
completion
Jul 31, 2030
last updated
Jul 1, 2026
official title
Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol